SG195038A1 - Dry powder vancomycin compositions and associated methods - Google Patents

Dry powder vancomycin compositions and associated methods Download PDF

Info

Publication number
SG195038A1
SG195038A1 SG2013085394A SG2013085394A SG195038A1 SG 195038 A1 SG195038 A1 SG 195038A1 SG 2013085394 A SG2013085394 A SG 2013085394A SG 2013085394 A SG2013085394 A SG 2013085394A SG 195038 A1 SG195038 A1 SG 195038A1
Authority
SG
Singapore
Prior art keywords
composition
vancomycin
dry powder
value
present disclosure
Prior art date
Application number
SG2013085394A
Other languages
English (en)
Inventor
John Lord
Jaakko Taneli Jouhikainen
Herman E Snyder
Pravin Soni
Mei-Chang Kuo
Original Assignee
Savara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savara Inc filed Critical Savara Inc
Publication of SG195038A1 publication Critical patent/SG195038A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG2013085394A 2011-05-19 2012-05-21 Dry powder vancomycin compositions and associated methods SG195038A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487971P 2011-05-19 2011-05-19
PCT/US2012/038775 WO2012159103A1 (en) 2011-05-19 2012-05-21 Dry powder vancomycin compositions and associated methods

Publications (1)

Publication Number Publication Date
SG195038A1 true SG195038A1 (en) 2013-12-30

Family

ID=47177374

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013085394A SG195038A1 (en) 2011-05-19 2012-05-21 Dry powder vancomycin compositions and associated methods

Country Status (11)

Country Link
EP (1) EP2709646A4 (enExample)
JP (1) JP6012716B2 (enExample)
KR (1) KR101763195B1 (enExample)
CN (1) CN103717231B (enExample)
AU (1) AU2012254999B2 (enExample)
BR (1) BR112013029803B1 (enExample)
CA (2) CA2836643C (enExample)
IL (1) IL229506B (enExample)
MX (1) MX346244B (enExample)
SG (1) SG195038A1 (enExample)
WO (1) WO2012159103A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
CA2891487A1 (en) * 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
CN104043104B (zh) * 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
JP2017510563A (ja) * 2014-02-28 2017-04-13 アルギファルマ エーエス 嚢胞性線維症及び欠陥ｃｆｔｒイオンチャネル機能に関連する他の病態の治療におけるアルギネートオリゴマーの使用
ES3057232T3 (en) 2014-03-14 2026-02-27 Azurity Pharmaceuticals Inc Composition and method for vancomycin oral liquid
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
WO2016071495A1 (en) 2014-11-06 2016-05-12 Xellia Pharmaceuticals Aps Glycopeptide compositions
EP3253391B1 (en) 2015-02-06 2021-09-08 Latitude Pharmaceuticals Incorporated Aqueous solution formulations of vancomycin
GB201609940D0 (en) 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
CN106963939A (zh) * 2017-03-22 2017-07-21 永信药品工业（昆山）股份有限公司 盐酸万古霉素药物组合物及其制备方法
GB2577420B (en) * 2017-05-22 2022-07-06 Insmed Inc Glycopeptide derivative compounds and uses thereof
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
WO2020081599A1 (en) * 2018-10-15 2020-04-23 Savara Inc. Separation of vancomycin and its degradation products
EP3866775B1 (en) 2018-10-17 2025-03-19 Novabiotics Limited Cysteamine for use in the treatment of lung diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH03193735A (ja) * 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP4142149B2 (ja) * 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
EP1992335A1 (en) * 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
DE10358387A1 (de) * 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
FR2872044B1 (fr) * 2004-06-28 2007-06-29 Flamel Technologies Sa Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
AU2009302478B2 (en) * 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
AU2010229721A1 (en) * 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
JP5671001B2 (ja) 2009-03-26 2015-02-18 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法

Also Published As

Publication number Publication date
KR101763195B1 (ko) 2017-07-31
CA2981038C (en) 2018-09-25
NZ618002A (en) 2015-03-27
BR112013029803B1 (pt) 2021-07-13
CA2836643A1 (en) 2012-11-22
NZ704819A (en) 2016-05-27
JP2014515356A (ja) 2014-06-30
JP6012716B2 (ja) 2016-10-25
CA2836643C (en) 2017-11-14
IL229506A0 (en) 2014-01-30
MX2013013503A (es) 2014-05-12
IL229506B (en) 2019-07-31
EP2709646A4 (en) 2015-05-13
BR112013029803A2 (pt) 2017-01-17
EP2709646A1 (en) 2014-03-26
CN103717231A (zh) 2014-04-09
CN103717231B (zh) 2016-08-17
MX346244B (es) 2017-03-13
WO2012159103A1 (en) 2012-11-22
CA2981038A1 (en) 2012-11-22
KR20140032450A (ko) 2014-03-14
AU2012254999B2 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
CA2836643C (en) Dry powder vancomycin compositions and associated methods
AU2012254999A1 (en) Dry powder vancomycin compositions and associated methods
US7473433B2 (en) Pulmonary delivery of polyene antifungal agents
CA2468958C (en) Pulmonary delivery of aminoglycosides
US9539233B2 (en) Gallium formulation for the treatment and prevention of infectious diseases
US20210154137A1 (en) Dry powder vancomycin compositions and associated methods
AU2002245181A1 (en) Pulmonary delivery of polyene antifungal agents
JP2008503586A (ja) アンフォテリシンｂを含む組成物、方法、およびシステム
WO2013104892A1 (en) Application of high dose compounds via inhalation
WO2006033713A2 (en) Methods for ciprofloxacin inhalation
NZ618002B2 (en) Dry powder vancomycin compositions and associated methods
WO2023177367A1 (en) Dosage forms of active substances used against viral diseases in dry powder inhaler device for symptoms caused by covid-19 and other viral lung diseases
Aygüler et al. An overview of dry powder inhaler production methods
Auriemma et al. Gentamicin and particle engineering: from an old molecule to innovative drug delivery systems
CN104208060A (zh) 一种青霉素类抗生素的吸入制剂